Regeneron Pharmaceuticals (REGN) Gross Margin (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Gross Margin of 91.59% for Q2 2026, down 91.0% year-over-year from 1017.7% in Q2 2025, and up 2.18% quarter-over-quarter from 89.64% in Q1 2026.
Regeneron Pharmaceuticals (REGN) Gross Margin (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Gross Margin history runs 18 years deep, the most recent figure standing at 91.59% for Q2 2026.
- In Q2 2026, Gross Margin fell 91.0% year-over-year to 91.59%; the TTM figure through Jun 2026 stood at 91.41% (down 63.0% YoY), while the FY2025 annual figure was 92.05%, down 30.0% from the prior year.
- Gross Margin for Q2 2026 stood at 91.59%, up from 89.64% in the prior quarter.
- The five-year high for Gross Margin was 94.78% in Q2 2022, with the low at 314.6% in Q1 2022.
- The 5-year median for Gross Margin is 92.41% (2023), against an average of 54.78%.
- The sharpest annual moves came in 2022 and 2023: Gross Margin sank 40736 bps in 2022, then jumped 40672 bps in 2023.
- Regeneron Pharmaceuticals' Gross Margin stood at 178.0% in 2022, then jumped by 152 bps to 92.47% in 2023, then retreated by 1 bps to 91.38% in 2024, then gained by 0 bps to 91.8% in 2025, then decreased by 0 bps to 91.59% in 2026.
- Business Quant data shows REGN's Gross Margin at 91.59% in Q2 2026, 89.64% in Q1 2026, and 91.8% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 80.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91.59% |
| Mar 31, 2026 | 91.79% |
| Dec 31, 2025 | 96.45% |
| Sep 30, 2025 | 92.52% |
| Jun 30, 2025 | 92.50% |
| Mar 31, 2025 | 93.44% |
| Dec 31, 2024 | 88.32% |
| Sep 30, 2024 | 92.95% |
| Jun 30, 2024 | 93.73% |
| Mar 31, 2024 | 93.85% |
| Dec 31, 2023 | 92.47% |
| Sep 30, 2023 | 93.32% |
| Jun 30, 2023 | 93.27% |
| Mar 31, 2023 | 93.41% |
| Dec 31, 2022 | -178.00% |
| Sep 30, 2022 | 93.99% |
| Jun 30, 2022 | 94.78% |
| Mar 31, 2022 | -314.60% |
| Dec 31, 2021 | 106.00% |
| Sep 30, 2021 | 93.08% |